Articles
-
1 day ago |
cellandgene.com | Erin Harris |Dan Nelson |CARR Biosystems |Royce Tourtillott
Setting the Standard in CGT: Perspectives on Performance, Scalability, and Regulatory ComplianceExplore the evolving landscape of cell and gene therapy with insights from key opinion leaders. This white paper addresses challenges in process development and manufacturing across different modalities. Discover how end-to-end solutions can accelerate commercialization by prioritizing performance and scalability while simplifying the path to regulatory approvals.
-
1 day ago |
cellandgene.com | Erin Harris
By Erin Harris, Editor-In-Chief, Cell & Gene Follow Me On Twitter @ErinHarris_1 In today’s turbulent biotech landscape, companies are being forced to rethink their strategies across every stage of development. Recently, I had the opportunity to sit down with Dr. Ali Pashazadeh, Founder of Treehill Partners, for a conversation in which he offered a candid and informed perspective on the financial pressures facing the CGT space and the strategic pivots that could help biotechs move forward.
-
2 weeks ago |
cellandgene.com | Erin Harris
By Erin Harris, Editor-In-Chief, Cell & Gene Follow Me On Twitter @ErinHarris_1 Cynata Therapeutics, a Melbourne, Australia-based regenerative medicine company, is pioneering a new era in cell therapy with its Cymerus platform.
-
2 weeks ago |
advancingrna.com | Anna Welch |Advancing RNA |Erin Harris
Is The mRNA Payload The Real MVP Of Targeted Delivery? As one delightfully colorful quote from a panel discussion at the AMM Ascent meeting last fall reminds us, there’s a lot more to be explored, discussed, and understood as it relates to the mRNA cargo’s role in targeted delivery.
-
2 weeks ago |
cellandgene.com | Erin Harris
By Erin Harris, Editor-In-Chief, Cell & Gene Follow Me On Twitter @ErinHarris_1 During last month’s Cell & Gene Live, Emerging Technologies for Cell Therapy Manufacturing, I had the pleasure of conversing with our expert panelists, Rohit Ingale, Head of Manufacturing & MSAT at Arcellx and David O’Donnell, Vice President, Head of Manufacturing at Vor Bio about the biggest challenges and promising innovations in cell therapy manufacturing.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 960
- Tweets
- 1K
- DMs Open
- No
RT @_CellandGene: On #CellAndGenePodcast, @ArrowheadPharma CMO Javier San Martin shares the roadmap for #RNAi as well as the company's pipe…
RT @_CellandGene: CGT manufacturers that deprioritize cybersecurity efforts risk their ecosystem being vulnerable to cyber-attacks that can…
RT @_CellandGene: Walter Strapps, CEO of @Carver_Bio states that when it comes to #mRNA, the challenges associated with its delivery are an…